Clinical Trials Logo

Pigment Epithelial Detachment clinical trials

View clinical trials related to Pigment Epithelial Detachment.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03370380 Completed - Clinical trials for Pigment Epithelial Detachment

Aflibercept in Patients With Pigment Epithelial Detachments (PED)

Start date: April 17, 2015
Phase:
Study type: Observational

Uncontrolled single site non randomized non interventional study to determine the safety and efficacy of intravitreal injections of Aflibercept in patients with recent vision loss due to retinal pigment epithelial detachment secondary to AMD

NCT ID: NCT00976222 Completed - Clinical trials for Pigment Epithelial Detachment

Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments

Start date: December 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).

NCT ID: NCT00841581 Completed - Clinical trials for Pigment Epithelial Detachment

Lucentis to Treat Pigment Epithelial Detachment

Start date: December 2008
Phase: Phase 2
Study type: Interventional

Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.

NCT ID: NCT00590694 Completed - Clinical trials for Age-related Macular Degeneration

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

DETAIL
Start date: October 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Patients with neovascular Age-related macular degeneration (AMD) and the particular feature of pigment epithelial detachments (PEDs) were not studied in the Phase III trials for ranibizumab (Lucentis). The PrONTO study was the first ranibizumab study to enroll such patients but only treated with ranibizumab until fluid within the layers of the retina was absent, not until the entire PED was absent. This study hypothesizes that there may be a difference in benefit between patients treated until just the retinal edema is gone and those in which the retinal edema and PED are both gone.